Table 11.

Clinical studies of β₃AR agonist.

Drug	Study Population	Treatment	Primary and Secondary Endpoints	Main Findings and Conclusion
Mirabegron (BEAT-HF trial) [143]	▪HF patients with NYHA II–III and LVEF < 40% (N = 70).	Mirabegron titrated to 150 mg BID or placebo for 6 months	Primary: ▪Change in LVEF from baseline to 6 months.	▪The primary endpoint of the study was not met. ▪From exploratory analysis, mirabegron was associated with increased LVEF in patients with severe HF.
Mirabegron (BEAT-HF-II trial) [90]	▪HF patients with NYHA III–IV and LVEF < 35%. ▪Increased NT-proBNP levels (N = 22).	Mirabegron 300 mg daily or placebo for one week	▪Invasive hemodynamic measurements. ▪Changes in cardiac index, SV index, HR, systemic vascular resistance (SVR), BP, and renal function.	▪Mirabegron was associated with increased cardiac index and decreased pulmonary vascular resistance. ▪No significant differences in changes in HR, SVR, BP, or renal function.